Press Release in connection with Un- Audited Financial Results of the Company for the Quarter Ended 30th June, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 27 Jul 2026, 07:28 PM IST · BSE ID: a34ae5ff-cd5c-4a7c-adb3-86cbf5ecabbb
View Original BSE Filing (PDF)
💡
In Simple Terms
Balaji Amines reported increased profits and revenue for the latest quarter, and started a new large chemical plant.
🤖 AI Summary
- Balaji Amines reported consolidated net profit of ₹ 78 Crore for Q1 FY27, compared to ₹ 37 Crore in Q1 FY26.
- Consolidated revenue from operations for Q1 FY27 stood at ₹ 461 Crore, up from ₹ 367 Crore in Q1 FY26.
- Consolidated EBITDA for Q1 FY27 was ₹ 121 Crore, with an EBITDA margin of 26%.
- The company commissioned India's first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant during Q1 FY27.
- Expansion projects including N-Methyl Morpholine (NMM) and Acetonitrile (ACN) capacity are expected in FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Total Revenue
₹ 461 Crore
25.61%
Consolidated EBITDA
₹ 121 Crore
89.06%
Consolidated EBITDA Margin
26%
Consolidated PAT
₹ 78 Crore
110.81%
Consolidated PAT Margin
17%
Consolidated Sales Volume
21,587 MT
-21.62%
🏢 How This Affects the Company
The commissioning of the 100,000 TPA Dimethyl Ether (DME) plant marks strategic entry into alternate fuel applications, expanding the company's product portfolio and market segments. Ongoing expansion in specialty chemicals through Balaji Speciality Chemicals Limited aims to build indigenous capabilities in cyanide chemistry.
Consolidated PAT increased to ₹ 78 Crore in Q1 FY27 from ₹ 37 Crore in Q1 FY26, and EBITDA margin improved to 26% from 17% in the same prior-year quarter. This reflects improved operational profitability.
New projects like N-Methyl Morpholine (NMM) and Acetonitrile (ACN) capacity expansion, along with the Balaji Speciality Chemicals ₹ 750 Crore expansion, will significantly increase manufacturing capacity and product diversity. Total sales volume decreased to 21,587 MT in Q1 FY27 from 27,570 MT in Q1 FY26.
The diversification into new-age chemicals and alternate fuel applications may reduce reliance on existing product segments, potentially diversifying business risks. Investment in indigenous capabilities for critical intermediates could reduce import reliance risks.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the increase in consolidated net profit to ₹ 78 Crore and revenue to ₹ 461 Crore for Q1 FY27. Diluted EPS for Q1 FY27 stood at ₹ 23.13.
🔍
Management Signal
Management is focused on operational efficiency, diversifying product portfolio through new project commissioning, and expanding specialty chemicals capabilities to capture structural growth opportunities.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Progress on N-Methyl Morpholine (NMM) and Acetonitrile (ACN) commissioning in FY27.
Updates on Balaji Speciality Chemicals' ₹ 750 Crore expansion program.
Q2 FY27 financial results — check revenue and profit trends.
LOW RISK
Strong financial performance and ongoing expansion projects mitigate immediate operational risks.
💡 Investor Takeaway
Balaji Amines reported Q1 FY27 consolidated net profit of ₹ 78 Crore, a 110.81% increase from ₹ 37 Crore in Q1 FY26. Consolidated revenue was ₹ 461 Crore, up 25.61% YoY. The company commissioned India's first 100,000 TPA Dimethyl Ether (DME) plant.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Net Profit (PAT) increased to ₹ 78 Crore in Q1 FY27 from ₹ 37 Crore in Q1 FY26, representing a 110.81% YoY increase.
- Consolidated EBITDA margin improved to 26% in Q1 FY27, up from 17% in Q1 FY26 and 25% in Q4 FY26.
⚠️ Concerns
- Consolidated Sales Volume decreased to 21,587 MT in Q1 FY27 from 27,570 MT in Q1 FY26, representing a 21.62% YoY decline.
- Amines volumes stood at 6,248.57 MT in Q1 FY27, indicating a specific segment's contribution to the overall volume reduction.
📅 Company Track Record
Balaji Amines reported Q1 FY27 consolidated net profit up 113.84% to Rs. 7,811.77 Lakhs (₹ 78.11 Crore), building on Q4 FY26 consolidated net profit up 62.50% to ₹ 65 Crore. FY26 profit was Rs 16,552.83 Lakhs (₹ 165.53 Crore), with a recommended Rs 11/- dividend.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Balaji Amines' consolidated net profit for Q1 FY27?
Balaji Amines reported a consolidated net profit (PAT) of ₹ 78 Crore for the quarter ended June 30th, 2026 (Q1 FY27).
What was Balaji Amines' consolidated total revenue in Q1 FY27?
The consolidated total revenue for Balaji Amines in Q1 FY27 was ₹ 461 Crore.
How did Balaji Amines' EBITDA margin perform in Q1 FY27?
The consolidated EBITDA margin for Balaji Amines in Q1 FY27 stood at 26%, compared to 17% in Q1 FY26.
What new project did Balaji Amines commission in Q1 FY27?
Balaji Amines successfully commissioned India's first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant during Q1 FY27.
What was the consolidated sales volume for Balaji Amines in Q1 FY27?
Consolidated sales volume for Balaji Amines in Q1 FY27 was 21,587 MT.
Questions based on this BSE filing only. For information purposes.